Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTRA1 | Q92743 | 1/20 | 0.46 |
| ▸ | AGTR2 | P50052 | 3/20 | 0.45 |
| ▸ | GRIN2B | Q13224 | 3/20 | 0.45 |
| ▸ | NAMPT | P43490 | 1/20 | 0.43 |
| ▸ | HCRTR2 | O43614 | 1/20 | 0.43 |
| ▸ | SLC18A3 | Q16572 | 4/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.40 |
| ▸ | NR1H2 | P55055 | 2/20 | 0.40 |
| ▸ | NR1H3 | Q13133 | 2/20 | 0.40 |
| ▸ | TP53 | P04637 | 2/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4074855 | 1.00 | HTRA1 (0.46) | HTRA1AGTR2GRIN2BNAMPTHCRTR2 | |
| SCHEMBL27764385 | 0.84 | GRIN2B (0.51) | AGTR2GRIN2BSLC18A3KDM4EALDH1A1 | |
| SCHEMBL15730092 | 0.84 | HTRA1 (0.53) | HTRA1NAMPTHCRTR2GPR119NR1H2 | |
| SCHEMBL15730122 | 0.84 | HTRA1 (0.53) | HTRA1NAMPTHCRTR2GPR119NR1H2 | |
| SCHEMBL4206100 | 0.84 | HTRA1 (0.53) | HTRA1NAMPTHCRTR2GPR119NR1H2 | |
| SCHEMBL4196684 | 0.84 | HTRA1 (0.53) | HTRA1NAMPTHCRTR2GPR119NR1H2 | |
| SCHEMBL18853751 | 0.84 | HTRA1 (0.53) | HTRA1NAMPTHCRTR2GPR119NR1H2 | |
| SCHEMBL24700140 | 0.83 | NAMPT (0.46) | HTRA1NAMPTHCRTR2SLC18A3KDM4E | |
| SCHEMBL24700143 | 0.80 | HCRTR2 (0.47) | HTRA1NAMPTHCRTR2GPR119NR1H2 | |
| SCHEMBL4077656 | 0.80 | NAMPT (0.54) | GRIN2BNAMPTKDM4EALDH1A1GPR119 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8754107-B2 | Aminopyrrolidines as chemokine receptor antagonists | ABBVIE INC. (US) | 2014-06-17 | — | — | US | disclosed |
| US-20080176883-A1 | Antiinflammtory, antiproliferative, anticancer agents; (3-Hydroxy-pyrrolidin-1-yl)-(3-trifluoromethyl-7,8-dihydro-5H-[1,6]naphthyridin-6-yl)-methanone | ABBVIE INC. | 2008-07-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080176883-A1 | Antiinflammtory, antiproliferative, anticancer agents; (3-Hydroxy-pyrrolidin-1-yl)-(3-trifluoromethyl-7,8-dihydro-5H-[1,6]naphthyridin-6-yl)-methanone | MIF, CCL5, CCR2 | HTRA1 1549/4885AGTR2 280/4885GRIN2B 2662/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.